Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TTR | P02766 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938748 | 0.84 | KEAP1 (0.50) | KEAP1CES2CES1KDM4EALDH1A1 | |
| SCHEMBL29955424 | 0.82 | PARP1 (0.46) | KEAP1CES2CES1LMNA | |
| SCHEMBL29920551 | 0.79 | SLC6A4 (0.50) | CES2CES1KDM4EALDH1A1HPGD | |
| SCHEMBL458104 | 0.79 | SLC6A4 (0.50) | CES2CES1KDM4EALDH1A1HPGD | |
| Boric Acid SCHEMBL29160824 | 0.79 | KEAP1 (0.59) | KEAP1CES2CES1KDM4EALDH1A1 | |
| SCHEMBL22190040 | 0.79 | KEAP1 (0.63) | KEAP1CES2CES1KDM4EALDH1A1 | |
| SCHEMBL2352988 | 0.78 | CSNK2A1 (0.59) | KDM4EALDH1A1TTRMEN1CA1 | |
| SCHEMBL9937971 | 0.78 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL336978 | 0.76 | KEAP1 (0.65) | KEAP1CES2CES1KDM4EALDH1A1 | |
| SCHEMBL30520290 | 0.76 | KEAP1 (0.65) | KEAP1CES2CES1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | claimed |
| EP-4588921-A1 | FREE BASE CRYSTAL FORM OF POLYCYCLIC COMPOUND OF NITROGEN-CONTAINING HETEROCYCLE, AND PREPARATION METHOD THEREFOR | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-105473550-B | IDO inhibitors | 百时美施贵宝公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-105473550-A | Ido inhibitors | BRISTOL MYERS SQUIBB CO | 2016-04-06 | — | — | CN | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | KEAP1 1892/4885CES2 4843/4885CES1 4424/4885 |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HCRTR1, HCRTR2, CCKBR | KEAP1 1172/4885CES2 3097/4885CES1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.